Overview

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Instituto do Cancer do Estado de São Paulo
Treatments:
Ivermectin
Losartan